Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by AlphaQuest LLC

AlphaQuest LLC raised its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 32,588.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,172 shares of the company's stock after purchasing an additional 8,147 shares during the period. AlphaQuest LLC's holdings in Akero Therapeutics were worth $227,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the stock. abrdn plc grew its position in Akero Therapeutics by 118.7% in the 4th quarter. abrdn plc now owns 269,782 shares of the company's stock valued at $7,505,000 after acquiring an additional 146,424 shares during the last quarter. FMR LLC boosted its stake in shares of Akero Therapeutics by 732.1% during the third quarter. FMR LLC now owns 30,337 shares of the company's stock valued at $870,000 after purchasing an additional 26,691 shares during the period. Proficio Capital Partners LLC bought a new position in shares of Akero Therapeutics in the fourth quarter worth about $320,000. SG Americas Securities LLC increased its stake in Akero Therapeutics by 4,022.1% in the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company's stock worth $16,636,000 after buying an additional 583,486 shares during the period. Finally, Barclays PLC lifted its holdings in Akero Therapeutics by 127.9% during the 3rd quarter. Barclays PLC now owns 127,668 shares of the company's stock valued at $3,662,000 after buying an additional 71,652 shares in the last quarter.

Wall Street Analyst Weigh In

AKRO has been the subject of several research analyst reports. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. UBS Group upped their target price on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a report on Friday, January 31st. HC Wainwright increased their price target on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Citigroup lifted their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $76.29.

Remove Ads

Insider Activity

In other news, insider Catriona Yale sold 10,000 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $49.87, for a total transaction of $498,700.00. Following the sale, the insider now directly owns 95,648 shares in the company, valued at $4,769,965.76. This trade represents a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Cheng sold 30,000 shares of the company's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $54.90, for a total value of $1,647,000.00. Following the completion of the transaction, the chief executive officer now directly owns 716,062 shares of the company's stock, valued at $39,311,803.80. The trade was a 4.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 252,135 shares of company stock valued at $12,345,079 in the last quarter. 7.94% of the stock is currently owned by company insiders.

Akero Therapeutics Stock Performance

NASDAQ AKRO traded up $1.24 on Wednesday, hitting $44.77. 453,025 shares of the company's stock traded hands, compared to its average volume of 810,083. The firm's 50-day moving average price is $42.78 and its two-hundred day moving average price is $34.13. The firm has a market capitalization of $3.56 billion, a PE ratio of -11.94 and a beta of -0.19. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 1-year low of $17.86 and a 1-year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). As a group, analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.